Skip to content

Ionis Pharmaceuticals IONS Early Repayment Of Convertible Debt

Early Repayment Of Convertible Debt at other companies

Cytokinetics logo
CytokineticsCYTK
$100.63M
Nutanix, Inc. logo
Nutanix, Inc.NTNX
$0-100%
MIT
TPG Mortgage Investment Trust MITT
$0
Roivant Sciences logo
Roivant SciencesROIV
$0
Take-Two Interactive Software logo
Take-Two Interactive SoftwareTTWO
$0
DexCom logo
DexComDXCM
$301.88M

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept ions:EarlyRepaymentOfConvertibleDebt.

The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's early repayment of convertible debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's early repayment of convertible debt?
Ionis Pharmaceuticals (IONS) reported early repayment of convertible debt of $66.91M in Q4 2025.
What does early repayment of convertible debt mean?
Cash paid to retire convertible debt before it is due.
How do you interpret early repayment of convertible debt?
An increase suggests the company is actively managing its capital structure or has excess liquidity to reduce debt obligations.
How does early repayment of convertible debt compare across companies?
Common in biotech companies managing capital structures; peers often report this during refinancing cycles.